Table 1. CIR of consensus pathology CIN2+ and CIN3+ stratified by different combinations of cervical cytology and HPV results.
| Strategy | Results of screening | No. (% of 21,568) | CIR (95% CI) | |||
|---|---|---|---|---|---|---|
| CIN2+ | CIN3+ | |||||
| Co-testing | Co-testing (negative) | 16,998 (78.81) | 0.18 (0.12–0.25) | 0.09 (0.04–0.13) | ||
| HR-HPV (+) &/or TCT ≥ASC-US | 4,570 (21.19) | 23.13 (21.91–24.35) | 15.84 (14.78–16.90) | |||
| TCT ≥(ASC-US)† & HR-HPV (−) | 636 (2.95) | 3.62 (2.17–5.07) | 2.04 (0.94–3.14) | |||
| TCT (NILM) & HR-HPV (+) | 2,028 (9.40) | 6.56 (5.48–7.64) | 2.82 (2.09–3.53) | |||
| TCT (NILM) & HPV-16/-18 (+) | 549 (2.55) | 16.03 (12.96–19.10) | 8.20 (5.90–10.49) | |||
| TCT (NILM) & HR-HPV non-16/18 (+) | 1,479 (6.86) | 3.04 (2.17–3.92) | 0.81 (0.35–1.27) | |||
| Cytology | TCT(NILM) | 19,026 (88.20) | 0.86 (0.73–0.99) | 0.38 (0.29–0.47) | ||
| TCT ≥ASC-US | 2,542 (11.78) | 36.35 (34.48–38.22) | 26.24 (24.53–27.95) | |||
| TCT (ASC-US) | 1,142 (5.29) | 16.55 (14.39–18.71) | 9.89 (8.16–11.63) | |||
| TCT ≥LSIL | 1,400 (6.49) | 52.50 (49.88–55.12) | 39.57 (37.01–47.13) | |||
| HR-HPV | HR-HPV (−) | 17,633 (81.80) | 0.30 (0.22–0.38) | 0.15 (0.10–0.21) | ||
| HR-HPV (+) | 3,935 (18.20) | 26.30 (24.93–27.68) | 18.09 (16.89–19.30) | |||
| HPV-16/-18 (+)* | 1,336 (6.19) | 48.28 (45.60–50.96) | 37.20 (34.61–39.79) | |||
| HR-HPV non-16/18 (+) | 2,599 (12.05) | 15.01 (13.63–16.38) | 8.27 (7.21–9.33) | |||
ASC-H, atypical squamous cells, not possible to exclude high-grade squamous intraepithelial lesion; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; CI, confidence interval; CIR, cumulative incidence rates; HR-HPV, high-risk human papillomavirus; NILM, negative for intraepithelial lesion or malignancy; TCT, thinprep cytologic test.
*Compared to the patients with non-HPV-16/-18 infection, the patients with HPV-16/-18 infection have a significantly increased risk for cancer; †Including ASC-H.